LXRX Overview
Upcoming Projects (LXRX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (LXRX)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (LXRX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (LXRX)
-
Lexicon (LXRX) Expects to Commence Phase 1 Study of LX9211 in Neuropathic Pain in 2017
Ticker: LXRX
Occurred on: Sep 27, 2017 -
Lexicon (LXRX) Expects inTandem3 Data Mid-Year Evaluating Sotagliflozin in Type 1 Diabetes
Ticker: LXRX
Occurred on: Jun 03, 2017 -
Lexicon Pharma (LXRX) Expects Commercial Launch of Telotristat Ethyl in Late Q1 for Patients with Carcinoid Syndrome
Ticker: LXRX
Occurred on: Mar 03, 2017 -
Lexicon (LXRX) Expects Initial Phase 1 Data in 2017 for LX2761 in Diabetes
Ticker: LXRX
Occurred on: Jan 09, 2017 -
Lexicon Pharma (LXRX) Presents Data from Phase 3 Tandem2 Trial Evaluating Orally Administered Sotagliflozin in Adult Type 1 Diabetics
Ticker: LXRX
Occurred on: Dec 21, 2016 -
Phase 3 data of Sotagliflozin (LX4211) for Type 1 Diabetes due 2H 2016
Ticker: LXRX
Occurred on: Sep 09, 2016
Strategic Initiatives (LXRX)
-
Lexicon Pharma (LXRX) Acquires Exclusive Research Rights from Bristol-Myers Squibb (BMY) for Neuropathic Pain Candidate LX9211
Tickers: BMY, LXRX
Announcement Date: Nov 07, 2016
